News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

LAM Pharmaceutical Corporation (LAMP) IPM Wound Gel (TM) Grants Distribution Rights For Brazil And Argentina


10/19/2005 5:13:20 PM

LEWISTON, New York, October 12 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. , a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it granted its Latin American distribution partner, aQva Pharmaceuticals, exclusive distribution rights for Brazil and Argentina.

Mr. Salvador Ficciella, CEO of aQva Pharmaceuticals stated, "We are very pleased to secure the exclusive distribution rights for Argentina and Brazil. Our company is looking forward to begin the second phase of registrations in two of the largest markets in Latin America and we are delighted to be able to represent LAM and the LAM IPM Wound Gel(TM) in both countries."

Mr. Joseph T. Slechta, President and Chief Executive Officer of LAM noted, "Granting aQva the Gel distribution rights for Brazil and Argentina is a natural extension of our cooperation with the company. We are very confident about aQva's ability to introduce LAM IPM Wound Gel(TM) into these two large markets."

About LAM Pharmaceutical, Corp.

For more information about LAM Pharmaceutical, Corp., please see our web site at www.lampharm.com.

About aQva Pharmaceuticals

aQva Pharmaceuticals is an international distribution company with headquarters in Montreal, Canada, an operating subsidiary in Mexico City and distribution partners in several Latin American Countries. aQva main business focus is to distribute pharmaceutical and healthcare products in Latin America.

Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

LAM Ionic Polymer Matrix(TM), LAM IPM(TM) and IPM Wound Gel(TM) are trademarks of LAM Pharmaceutical, Corp.

LAM IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.

Contact Stephanie Carrington (Investors/Media) +1-646-536-7017 The Ruth Group

LAM Pharmaceutical, Corp.

CONTACT: Stephanie Carrington, The Ruth Group, +1-646-536-7017


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES